Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
3.650
-0.080 (-2.14%)
At close: May 17, 2024, 4:00 PM
3.700
+0.050 (1.37%)
After-hours: May 17, 2024, 7:51 PM EDT
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Daniel J. O'Connell M.B.A. |
Contact Details
Address: 427 Park St. Charlottesville, Virginia 22902 United States | |
| Phone | 925-368-8508 |
| Website | acumenpharm.com |
Stock Details
| Ticker Symbol | ABOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001576885 |
| CUSIP Number | 00509G209 |
| ISIN Number | US00509G2093 |
| Employer ID | 36-4108129 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel J. O'Connell M.B.A. | Chief Executive Officer and Director |
| Matt Zuga | Chief Financial Officer and Chief Business Officer |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. James Doherty Ph.D. | President and Chief Development Officer |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Russell Barton M.S. | Chief Operating Officer |
| Kelly Carranza | Vice President, Finance and Accounting and Corporate Controller |
| Alex Braun M.B.A. | Vice President and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 24, 2024 | EFFECT | Notice of Effectiveness |
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |